Thioridazine, an antipsychotic drug, elicits potent antitumor effects in gastric cancer

JIASHENG MU1,2*, HAINENG XU3*, YU YANG3, WEIDAN HUANG3, JING XIAO4, MAOLAN LI1,2, ZHUJUN TAN1,2, QICHER DING1,2, LIN ZHANG1,2, JIANHUA LU1,2, XIANGSONG WU1,2 and YINGBIN LIU1,2

1Department of General Surgery and Laboratory of General Surgery, Xinhua Hospital, Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200092; 2Institute of Biliary Tract Disease, Shanghai Jiao Tong University School of Medicine, Shanghai 200092; 3State Key Laboratory of Cell Biology, Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai 200031; 4College of Life Science, Henan Normal University, Xinxiang, Henan 453007, P.R. China

Received January 10, 2014; Accepted February 13, 2014

DOI: 10.3892/or.2014.3068

Abstract. Thioridazine, an antipsychotic drug, has been reported to induce apoptosis in various types of cancer cells, with specificity on targeting cancer stem cells (CSCs). However, whether it elicits anticancer effects in gastric cancer has never been reported. In the present study, we examined the ability of thioridazine to induce cell death in the gastric cancer cell lines NCI-N87 and AGS, and detected its in vivo tumor inhibition capacity. Thioridazine elicited cytotoxic effects on NCI-N87 and AGS cells in a dose-dependent manner, and inhibited the colony formation ability of the NCI-N87 and AGS cells. Thioridazine treatment induced nuclear fragmentation, increased the proportion of sub-G1 phase cells, and elevated the percentage of Annexin V-positive cells, suggesting the occurrence of apoptosis. Moreover, thioridazine induced gastric cancer cell apoptosis in a caspase-dependent manner, as shown by a decrease in the precursors of caspase-9, caspase-8 and caspase-3, and by the ability of the caspase inhibitor Z-VAD-FMK to reverse the cytotoxic effect of thioridazine. JC-1 staining further revealed that thioridazine induced gastric cancer cell apoptosis via the mitochondrial pathway. In addition, thioridazine pretreatment inhibited the growth of NCI-N87 cell-derived tumors. The present study demonstrated that the antipsychotic drug thioridazine possesses anti-gastric cancer ability through in vitro and in vivo experiments, suggesting thioridazine as a potential drug in gastric cancer therapy.

Introduction

Gastric cancer is the fourth most common cancer worldwide with 989,600 new cases diagnosed in 2008, and it is the second leading cause of cancer-related death (1,2). Gastric cancer is either asymptomatic or causes non-specific symptoms at an early stage, and thus the majority of patients present with advanced stage disease at the time of initial diagnosis, leading to the poor prognosis of gastric cancer. Gastric cancer treatment involves surgery, chemotherapy, radiation therapy and their combinations. However, current drugs are confronted with low efficacy due to the high rate of patients at the advanced stage of gastric cancer. Thus, the development of novel effective drugs for gastric cancer therapy is urgently needed.

Thioridazine, an antagonist of the dopamine receptor D2 family proteins, was initially developed as an antipsychotic drug, and recently its anticancer function was revealed. Studies have revealed the antiproliferative and apoptosis induction capacities of thioridazine in neuroblastoma, glioma, leukemia, breast cancer, cervical cancer and endometrial cancer (3-6). A gene signature-based approach identified thioridazine as an inhibitor of PI3K/Akt signaling in ovarian cancer cells. It downregulated cell cycle regulators cyclin D1 and CDK4, and upregulated p21, p16 and p-CDC25A, leading to the G0/G1 phase arrest of the cells (7). Research on cervical and endometrial cancer cells disclosing the involvement of the PI3K/Akt/mTOR pathway in thioridazine-induced apoptosis further supported this finding (3). Thioridazine was also found to exhibit an anti-angiogenic effect through the FAK/mTOR pathway (8), which may act in inhibiting tumor growth in vivo.

*Contributed equally

Key words: thioridazine, antipsychotic drug, gastric cancer, apoptosis, caspase, mitochondria, in vivo
In addition, Byun et al (8) found that thioridazine inhibited cancer cell growth while sparing various types of normal cells (6).

Chemoresistance is one of the limitations to gastric cancer therapy and this issue must be remedied. Research has revealed the capacity of thioridazine to reverse the chemoresistance of cancer cells. Thioridazine was found to overcome the resistance of P388 murine leukemia cells to doxorubicin (9). Thioridazine was also able to reverse the chemoresistance of human KB carcinoma cells by increasing the accumulation of chemotherapeutic drugs doxorubicin, vinblastine and dactinomycin in the cells (10). Thioridazine in combination with verapamil exhibited enhanced ability to reverse the multidrug resistance of cancer cells (11). Moreover, thioridazine was found to inhibit the expression of P-glycoprotein and induce the apoptosis of ABCB1-overexpressing drug-resistant mouse lymphoma (12,13).

In 2012, through small molecule library screening, Sachlos et al (14) discovered that thioridazine exhibited anti-neoplastic pluripotent stem cell ability, without interfering with normal pluripotent stem cells. Furthermore, it reduced the function of leukemia stem cells while sparing the normal human repopulation cells, demonstrating thioridazine's specificity in targeting CSCs. As CSCs play a vital role in drug resistance, cancer relapse and metastasis, thioridazine may be an effective drug for cancer therapy by targeting CSCs. Since thioridazine has been safely used in the clinic for many years as an antipsychotic, it can be rapidly evaluated in the clinic as an anticancer drug. However, the antitumor effects of thioridazine on gastric cancer have never been disclosed, and to the best of our knowledge, the in vivo tumor inhibition capacity of thioridazine has only been reported in murine cancer cells (15).

In the present study, we examined the cytotoxic effects of thioridazine on gastric cancer cell lines NCI-N87 and AGS. Thioridazine reduced the cell viability of gastric cancer cells and inhibited the colony formation of NCI-N87 and AGS cells. Thioridazine induced gastric cancer cell apoptosis dependent on caspases and through the mitochondrial pathway. Moreover, thioridazine pretreatment inhibited the growth of NCI-N87 cell-derived tumors. The present study demonstrated the anticancer effects of thioridazine in gastric cancer cells, and its ability to inhibit human gastric cancer cell tumor growth in vivo, suggesting thioridazine as a candidate for gastric cancer therapy.

Materials and methods

Cell lines and cell culture. Gastric cancer cell lines NCI-N87 and AGS were obtained from the Cell Bank of the Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences (Shanghai, China). NCI-N87 cells were maintained in DMEM supplemented with 10% heat-inactivated fetal bovine serum (FBS), and AGS cells were cultured in F-12K with 10% FBS. Both types of cells were incubated at 37°C in an atmosphere with 5% CO2.

Analysis of cell viability. The NCI-N87 and AGS cells were plated in 96-well plates at a density of 104 cells/well, and were treated with thioridazine (Sigma) at indicated concentrations for 48 h. After incubation with 0.5 mg/ml 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) (Beyotime Institute of Biotechnology, Haimen, China) for another 4 h, the supernatant was discarded, and 100 μl DMSO (dimethyl sulfoxide) was added to dissolve the produced formazan crystals. The absorbance was measured on a microplate reader (Thermo Fisher Scientific) at a dual wavelength of 595 nm and 630 nm. The difference in the outcome of OD595 and OD630 was considered as the measure of cell viability.

Detection of apoptosis. The NCI-N87 and AGS cells were treated with thioridazine for 48 h, Cells were trypsinized into single cells, washed with PBS and binding buffer, and then

Observation of cytotoxicity. To directly observe the cytotoxic effects of thioridazine, NCI-N87 and AGS cells were seeded in 24-well plates and incubated with thioridazine at the indicated concentrations. Forty-eight hours post-treatment, the cells were directly observed using microscopy or stained with 2% crystal violet which was dissolved in 20% methanol solution.

Colony formation assay. The NCI-N87 cells were seeded into 6-well plates at 3,000 cells/well and treated with thioridazine at indicated concentrations after the cells recovered. The formed colonies were stained with 2% crystal violet 10 days later, washed and photographed. The AGS cells were seeded at 1,000 cells/well in 6-well plates, treated similarly to NCI-N87 cells, and were stained with crystal violet 6 days later.

Western blot analysis. Western blot analysis was performed according to standard procedures. In brief, cells were trypsinized following treatment for the indicated times, lysed using RIPA lysis buffer and boiled in SDS-PAGE sample loading buffer (both from Beyotime Institute of Biotechnology). Total protein (40 μg) was electrophoretically separated on 10 or 12% SDS-PAGE gel and transferred onto a polyvinylidene difluoride (PVDF) membrane. The PVDF membrane was blocked with milk, incubated with the primary antibodies and then with the secondary antibodies. Primary antibodies for caspase-9, caspase-8, caspase-3 and PARP were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA) and GAPDH was from CoWin Bioscience Co. (Beijing, China). All the secondary antibodies were obtained from Santa Cruz Biotechnology. Subsequently, the protein on the membrane was revealed using ECL reagents (Pierce Biotechnology, Rockford, IL, USA).

Detection of apoptosis. The NCI-87 and AGS cells were treated with thioridazine at indicated concentrations, and fixed with 4% paraformaldehyde (PFA) for 15 min 48 h post-treatment. The cells were then stained with Hoechst 33258 (Molecular Probes, Eugene, OR, USA) at 1 μg/ml for 1 min, washed with PBS and photographed under a fluorescence microscope.

Cell cycle analysis. The NCI-N87 and AGS cells were trypsinized following treatment with thioridazine for 48 h, and then resuspended in PBS and fixed with 70% ethanol overnight at -20°C. The fixed cells were centrifugated, washed with PBS and incubated with 20 μg/ml RNAase in a water bath at 37°C for 30 min. After been stained with 50 μg/ml PI for another 30 min, they were subjected to a fluorescence-activated cell sorting (FACS) instrument for analysis.

Hoechst 33258 staining. The AGS cells were treated with thioridazine at indicated concentrations, and fixed with 4% paraformaldehyde (PFA) for 15 min 48 h post-treatment. The cells were then stained with Hoechst 33258 (Molecular Probes, Eugene, OR, USA) at 1 μg/ml for 1 min, washed with PBS and photographed under a fluorescence microscope.
Thioridazine induces gastric cancer cell apoptosis. Thioridazine was previously found to induce cervical and endometrial cancer apoptosis. To detect whether thioridazine induces gastric cancer cell apoptosis, Hoechst 333258 staining was carried out. Severe nuclear fragmentation was observed in the AGS cells following treatment with thioridazine at 10 and 15 µM, but not in the cells treated with DMSO or thioridazine at a low dosage (Fig. 2A). As the appearance of nuclear fragmentation indicates the occurrence of apoptosis, the cell cycle distribution was analyzed in the treated and untreated cells. The proportion of sub-G1 phase cells in the NCI-N87 and AGS cells increased as the dosage of thioridazine was increased (Fig. 2B). Further detection by Annexin V/PI double staining assay revealed that thioridazine treatment resulted in an increase in the percentage of Annexin V-positive cells in both the NCI-N87 and AGS cells (Fig. 2C). The results indicate the occurrence of apoptosis in the thioridazine-treated gastric cancer cells.

Thioridazine induces gastric cancer cell apoptosis dependent on the caspases. To further clarify the mechanism of thioridazine-induced apoptosis, expression of a number of apoptosis-related proteins was analyzed. PARP cleavage was observed in the presence of thioridazine, which further supported the occurrence of apoptosis. Precursors of caspase-9, caspase-8 and caspase-3 were decreased in the NCI-N87 cells following the treatment of thioridazine for 48 h. Moreover, downregulation of precursors of caspase-9, caspase-8 and caspase-3 was observed in the AGS cells treated with 15 µM thioridazine for 24 or 48 h (Fig. 3A). These results indicate the involvement of caspases in thioridazine-induced apoptosis in a time- and dose-dependent manner. Furthermore, caspase inhibitor Z-VAD-FMK was able to reverse the cytotoxicity of thioridazine both in the NCI-N87 and AGS cells (Fig. 3B), suggesting that thioridazine induced gastric cancer cell apoptosis in a caspase-dependent manner.

Thioridazine induces cell apoptosis via the mitochondrial pathway. As caspase-9 is involved in the mitochondrial apoptosis pathway, a decreased level of caspase-9 precursor implied the breakdown of mitochondria in the thioridazine-induced apoptosis. JC-1 staining assay was then carried out to examine the alteration of mitochondria. The percentage of cells with loss of mitochondrial membrane potential increased from 21.7 to 40.2% in the NCI-N87 cells following treatment with 15 µM thioridazine (Fig. 4A), and this proportion increased from 12.5 to 49.8% in AGS cells (Fig. 4B). The loss of mitochondrial membrane potential, along with decreased caspase-9 (Fig. 3A), suggest that thioridazine induced gastric cancer cell death via the mitochondrial apoptosis pathway.

Thioridazine inhibits tumor growth in vivo. To test the in vivo activity of thioridazine on gastric cancer cells, NCI-N87 cells were pretreated with DMSO or 5 µM thioridazine for 24 h, and the cells were then injected subcutaneously into the nude mice at the left or right rear to compare their tumor formation ability. Thioridazine (5 µM) elicited little change in the cell viability of NCI-N87 cells (Fig. 1A); however, pretreatment with 5 µM thioridazine inhibited the growth of NCI-N87 cell-derived tumors (Fig. 5A), and this was consistent with the anticancer effect of thioridazine on gastric cancer cells.
thioridazine's ability to inhibit colony formation (Fig. 1D). Obviously smaller tumors were observed at the right rear region of the mice which were derived from the thioridazine-pretreated cells, and the resected tumors exhibited a similar result (Fig. 5B and C). Moreover, the weight of the tumors derived from the thioridazine-pretreated cells was lower than
the tumors derived from the cells pretreated with DMSO (Fig. 5D).

**Discussion**

Thioridazine has been reported to have antiproliferative capacity in cancer cells, and is capable of inducing cancer cell apoptosis in various types of cancers (3-6). However, the cytotoxic effect of thioridazine in gastric cancer cells has never been reported. The present study revealed that thioridazine reduced the cell viability of gastric cancer cells, inhibited gastric cancer cell colony formation, and induced gastric cancer cell apoptosis via the mitochondrial pathway. These results indicate that thioridazine possesses anti-gastric cancer ability. Further experiments disclosed that thioridazine pretreatment inhibited the *in vivo* growth of tumors derived from NCI-N87 cells. To the best of our knowledge, to date, there is no research concerning the *in vivo* inhibition of human tumor growth by thioridazine, but only research disclosing its ability to inhibit murine tumor growth (15). The present study further demonstrated the *in vivo* tumor inhibitory ability of thioridazine and disclosed its cytotoxic effect on gastric cancer cells, suggesting thioridazine as a candidate drug for gastric cancer therapy.

Previous studies have disclosed the ability of thioridazine to reverse chemoresistance, and thioridazine was able to prevent the exclusion of small molecules from cancer cells (10,12,16). This may explain the anti-CSC ability of thioridazine that was discovered by small molecule library screening (17). Thioridazine was found to have an influence
on cyclin and cyclin-dependent kinase (CDK) (3,7), which are correlated with the cell cycle and cell growth. Moreover, thioridazine inhibited the PI3K/Akt pathway (3,7), which plays a critical role in CSCs (18). Moreover, DRD2, which was antagonized by thioridazine, specifically regulated Wnt and Akt signaling (17). Thus, thioridazine may elicit its anti-CSC capacity by preventing the exclusion of small molecules out of CSCs and by inhibiting the Wnt and PI3K/Akt pathways in CSCs. However, this needs to be confirmed by further experiments. Thioridazine was previously found to reverse the chemoresistance of cancer cells, and a significant therapeutic outcome in combination with verapamil was noted (11). Thus, thioridazine may be considered as an adjuvant in combination with chemotherapeutic drugs for cancer therapy. Moreover, it may also be utilized to treat cancer cells together with viruses. Thioridazine is an antagonist of the dopamine receptor D2 family proteins, and analogues of thioridazine have also exhibited antitumor effects (15), implying the involvement of the dopamine receptor signaling pathway in cancer. Dopamine receptor family proteins have been reported to be correlated with cancer therapy (20,21). Thioridazine may elicit tumor growth inhibition in a dopamine receptor-dependent and -independent manner. Negative relationship of the expression on cyclin and cyclin-dependent kinase (CDK) (3,7), which are correlated with the cell cycle and cell growth. Moreover, thioridazine inhibited the PI3K/Akt pathway (3,7), which plays a critical role in CSCs (18). Moreover, DRD2, which was antagonized by thioridazine, specifically regulated Wnt and Akt signaling (17). Thus, thioridazine may elicit its anti-CSC capacity by preventing the exclusion of small molecules out of CSCs and by inhibiting the Wnt and PI3K/Akt pathways in CSCs. However, this needs to be confirmed by further experiments. Thioridazine was previously found to reverse the chemoresistance of cancer cells, and a significant therapeutic outcome in combination with verapamil was noted (11). Thus, thioridazine may be considered as an adjuvant in combination with chemotherapeutic drugs for cancer therapy. Moreover, it may also be utilized to treat cancer cells together with viruses. Thioridazine is an antagonist of the dopamine receptor D2 family proteins, and analogues of thioridazine have also exhibited antitumor effects (15), implying the involvement of the dopamine receptor signaling pathway in cancer. Dopamine receptor family proteins have been reported to be correlated with cancer therapy (20,21). Thioridazine may elicit tumor growth inhibition in a dopamine receptor-dependent and -independent manner. Negative relationship of the expression on cyclin and cyclin-dependent kinase (CDK) (3,7), which are correlated with the cell cycle and cell growth. Moreover, thioridazine inhibited the PI3K/Akt pathway (3,7), which plays a critical role in CSCs (18). Moreover, DRD2, which was antagonized by thioridazine, specifically regulated Wnt and Akt signaling (17). Thus, thioridazine may elicit its anti-CSC capacity by preventing the exclusion of small molecules out of CSCs and by inhibiting the Wnt and PI3K/Akt pathways in CSCs. However, this needs to be confirmed by further experiments. Thioridazine was previously found to reverse the chemoresistance of cancer cells, and a significant therapeutic outcome in combination with verapamil was noted (11). Thus, thioridazine may be considered as an adjuvant in combination with chemotherapeutic drugs for cancer therapy. Moreover, it may also be utilized to treat cancer cells together with viruses. Thioridazine is an antagonist of the dopamine receptor D2 family proteins, and analogues of thioridazine have also exhibited antitumor effects (15), implying the involvement of the dopamine receptor signaling pathway in cancer. Dopamine receptor family proteins have been reported to be correlated with cancer therapy (20,21). Thioridazine may elicit tumor growth inhibition in a dopamine receptor-dependent and -independent manner. Negative relationship of the expression
of DRD2 family protein and the prognosis of leukemia was revealed, and other antagonists of the DRD2 family were found to exhibit an effect against CSCs as well (17). These results suggest that blocking of DRD2 family proteins may inhibit the growth of cancer cells, even CSCs. Development of specific small molecules that target or knock down DRD2 family proteins may result in a favorable outcome. Overexpressing shRNA targeting DRD2 family proteins by oncolytic viruses, particularly specific tumor targeting vectors (22,23), may exhibit a great antitumor effect. However, selective agonist of DRD2 family proteins induced lung cancer cell apoptosis (24,25), and this was contrary with the effect of the function of DRD2 family proteins in leukemia (17). Thus, the strategy of targeting DRD2 needs to be considered in relation to different types of cancers.

To overcome gastric cancer, it is vital to combine prevention as well as effective therapy. Habits including the eating of fresh food, avoiding the consumption of cured food and smoking, detecting *Helicobacter pylori* infection and screening will reduce the incidence of gastric cancer (2). However, in regards to patients diagnosed with gastric cancer or even advanced gastric cancer, treatment using effective drugs is vital. In the present study, thioridazine exhibited favorable anti-gastric cancer effects in vitro and in vivo, suggesting its use as a promising candidate drug for gastric cancer therapy. Furthermore, its combination with other therapeutic drugs may exhibit favorable outcome in gastric cancer therapy.

Acknowledgements

The present study was supported by the National Natural Science Foundation of China (nos. 81172026, 81272402, 81301816 and 81172029), the Foundation of Shanghai Outstanding Academic Leaders (no. 11XD1403800), the National High Technology Research and Development Program (863 Program) (no. 2012AA022606), the Post-doctoral Research Foundation of China (no. 2012M511107), the Foundation for Interdisciplinary Research of Shanghai Jiao Tong University (no. YG2011ZD07), the Shanghai Science and Technology Commission Inter-governmental International Cooperation Project (12410705900), the Shanghai Science and Technology Commission Medical-Guiding Project (12401905800), the Program for Changjiang Scholars and the Post-doctoral Research Program of Shanghai (no. 12R21415300).

References


